Viking Therapeutics (VKTX) Equity Average (2015 - 2026)

Viking Therapeutics has disclosed Equity Average across 12 years of filings, most recently posting $570.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at $570.5 million, down 33.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $570.5 million (down 33.94% YoY), and the FY2025 annual result was $759.7 million, up 23.65% from the prior year.
• Equity Average came in at $570.5 million for Q1 2026 at Viking Therapeutics, down from $676.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $927.4 million in Q2 2024 to a low of $139.7 million in Q1 2023.
• The 5-year median for Equity Average is $570.5 million (2026), against an average of $522.0 million.
• Across the five-year window, Equity Average jumped 358.97% in 2024 and tumbled 33.94% in 2026, its largest moves.
• Viking Therapeutics' Equity Average stood at $148.3 million in 2022, then jumped by 141.62% to $358.3 million in 2023, then surged by 150.01% to $895.9 million in 2024, then retreated by 24.54% to $676.0 million in 2025, then decreased by 15.61% to $570.5 million in 2026.
• The last three Equity Average figures came in at $570.5 million (Q1 2026), $676.0 million (Q4 2025), and $754.2 million (Q3 2025), per Business Quant data.